Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/5bc347c5-2596-4854-abdd-3ac604dae1fe/

TEVA

Teva Pharma Industries Ltd ADR
Chart
$34.19
Latest Week 2026-06-05
HealthcareDrug Manufacturers - Specialty & GenericLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.5
OS Score
12.0%
Value
77.0%
Quality
92.0%
Momentum
8/9
F-Score
0.304
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 101%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
RAM 2.60
V
Value Analysis
Cheapness relative to fundamentals
12.0%ile
P/E
25.8×
P/S
2.3×
P/B
4.9×
E/P
0.0388
FCF Yield
0.042
EBITDA/EV
0.061
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
87.00000000
/100 — 1=cheapest
VC2 (Trending Value)
91.00000000
/100
VC3 (Buyback)
91.00000000
/100
VC2 score of 91.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
77.0%ile
ROE
0.190
ROA
0.039
Net Margin
0.090
Op Margin
0.131
GPA
0.226
D/E
3.87
Current
1.01
F-Score
8/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.044
Stability
13.859
lower=better
Accruals
-0.004
lower=better
5yr Consist
No
Highly leveraged with D/E of 3.87 — returns are being amplified by debt. F-Score of 8/9 indicates strong fundamental improvement across multiple dimensions.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
92.0%ile
6M Return
20.1%
12M Return
92.4%
12-1 Mom
101.1%
Risk-Adj
2.60
Vol 252d
38.9%
Vol 60d
91.5%
↑ Expanding
Max DD 12M
-17.6%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 101% is very strong — a clear uptrend. Risk-adjusted momentum of 2.60 is excellent — strong returns relative to volatility. Near-term vol (91%) is expanding vs long-term (39%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.5
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
4.6%
Sector Quality %ile
84.6%
P/E z-score
0.00
P/B z-score
-0.01
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Quality Momentum — Expensive
Strong quality (77th) and momentum (92th) but expensive (12th value). Premium priced — watch for mean reversion.
Leveraged Returns
Strong ROE (19%) boosted by high leverage (D/E 3.9). Returns look good but come with balance sheet risk.
Quality at a Premium
High quality (77th) but expensive (12th value). Upside may be limited without earnings growth.
Volatility Expanding
60-day vol (91%) significantly exceeds 252-day (39%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
41.9% avg (7 factors)
Quality
D
37.8% avg (8 factors)
Momentum
A
88.2% avg (4 factors)
Risk
C
51.8% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.500—0—
Value %ile0.120—1—
Quality %ile0.770—1—
Momentum %ile0.920—1—
F-Score8.000—1—
Confidence0.939—1—
Volatility0.389—0—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
25.77
Earnings Yield (E/P)
0.0388
Price / Sales
2.32
Price / Book
4.90
Price / Cash Flow
23.52
FCF Yield
4.2%
EBITDA / EV
6.1%
Sales Yield (1/P·S)
0.3261
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
19.0%
Return on Assets
3.9%
Net Margin
9.0%
Operating Margin
13.1%
Gross Profit / Assets
Novy-Marx GPA
22.6%
Debt / Equity
3.87
Current Ratio
1.01
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.004
MomentumPrice trend strength over different horizons
6M Return
20.1%
12M Return
92.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
101.1%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
2.60
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
4.4%
Earnings Stability (CV)
Lower = more stable
13.859
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
8
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
87
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
91
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
91
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity